Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate vs Delayed Switch to Paliperidone Palmitate in Schizophrenia
NCT01682161Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2012
- Primary completion
- Sep 2013
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Jan 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01682161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682161.